These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23826879)

  • 21. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
    Zhao K; Ding M; Cao H; Cao ZX
    J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
    Jacobson PA; Green K; Birnbaum A; Remmel RP
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
    Obach RS
    Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats.
    Levin ED; Wells C; Hawkey A; Holloway Z; Blair G; Vierling A; Ko A; Pace C; Modarres J; McKinney A; Rezvani AH; Rose JE
    Psychopharmacology (Berl); 2020 Jun; 237(6):1681-1689. PubMed ID: 32125484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
    Meyers NL; Hickling RI
    Drugs R D; 2008; 9(1):37-63. PubMed ID: 18095752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY; Chen C; Yang Z; Rodrigues AD
    Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
    Totah RA; Allen KE; Sheffels P; Whittington D; Kharasch ED
    J Pharmacol Exp Ther; 2007 Apr; 321(1):389-99. PubMed ID: 17259447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
    Naritomi Y; Terashita S; Kagayama A
    Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of tauromustine in liver and lung microsomes from various species.
    Tuvesson H; Gunnarsson PO; Seidegård J
    Xenobiotica; 1999 Aug; 29(8):783-92. PubMed ID: 10553719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.